Search

Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.

• e-Newsletter
• Written

Next month, Anisha and Sheena will take on The Thames Path Challenge. Together, they explain why they decided to join #TeamRetinaUK.

• News
• Retinitis pigmentosa

We provide funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease.

Prof Dominic Ffytche will provide an explanation of what Charles Bonnet Syndrome is, the science behind it, and share some potential coping strategies for people who experience visual hallucinations.

• Webinar
• Video

Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.

• News
• Retinitis pigmentosa

Retina UK has a number of online support resources which we offer via social media.

Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.

We talk to BBC reporter Ramadan Younes and Professor Robert Maclaren following the BBC documentary Blind Faith

• Podcast
• Audio

Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.

• News
• Retinitis pigmentosa

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written